Recent Updates
Recently added Catalysts
SGHT Positive Sentiment

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

Key Takeaway: Sight Sciences, Inc. will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023. The presentation will showcase the company's commitment to transforming eye care through innovative technology. Notably, their products include the OMNI Surgical System for glaucoma and the TearCare System for dry eye disease. This event offers a platform for the company to enhance its profile among investors and industry stakeholders.
Price reaction · baseline $6.84 (2023-08-29 close) · hit after-hours · clean, no other SGHT news in the window
day 0 close · peak
-4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sight Sciences is presenting at a significant healthcare conference, highlighting its visibility in the industry.
  • The company's focus on innovative technology aims to improve patient care and treatment paradigms.
  • Products like the OMNI Surgical System and TearCare System show the company's commitment to addressing prevalent eye diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~42 mo
Low dilution risk
Lead asset
Restasis
Phase 1 · Ocular Surface Disease

Full Press Release Details

MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY.
Sight Sciences’ management is scheduled to present on Tuesday, September 12, 2023, at 12:35 pm PT / 3:35 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare System technology is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD) when used in conjunction with manual expression of the meibomian glands, enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight Sciences.
SION is a trademark of Sight Sciences.

Frequently Asked Questions

What is Sight Sciences focused on?

Sight Sciences specializes in innovative eyecare technology to enhance patient care.

When is Sight Sciences presenting at the conference?

The presentation is scheduled for September 12, 2023, at 12:35 pm PT.

What is the OMNI® Surgical System used for?

The OMNI® Surgical System is designed for minimally invasive glaucoma surgery.

What does the TearCare System treat?

The TearCare System addresses evaporative dry eye disease caused by MGD.

Where can I find more information about Sight Sciences?

Additional information is available on their official website, sightsciences.com.

Last updated: Aug 30, 2023